

# Ryuya Yamanaka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8589754/publications.pdf>

Version: 2024-02-01

111  
papers

3,045  
citations

172207

29  
h-index

189595

50  
g-index

112  
all docs

112  
docs citations

112  
times ranked

3559  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial. <i>Clinical Cancer Research</i> , 2005, 11, 4160-4167.	3.2	301
2	Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. <i>British Journal of Cancer</i> , 2003, 89, 1172-1179.	2.9	251
3	Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma. <i>Clinical Cancer Research</i> , 2005, 11, 5900-5911.	3.2	130
4	EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2768-2778.	1.9	119
5	A Novel Human CCAAT/Enhancer Binding Protein Gene, C/EBP $\beta$ , Is Expressed in Cells of Lymphoid and Myeloid Lineages and Is Localized on Chromosome 14q11.2 Close to the T-Cell Receptor $\alpha/\zeta$ Locus. <i>Genomics</i> , 1996, 35, 30-38.	1.3	111
6	Identification of expressed genes characterizing long-term survival in malignant glioma patients. <i>Oncogene</i> , 2006, 25, 5994-6002.	2.6	101
7	Radiation-Induced Meningiomas: An Exhaustive Review of the Literature. <i>World Neurosurgery</i> , 2017, 97, 635-644.e8.	0.7	75
8	Cell- and peptide-based immunotherapeutic approaches for glioma. <i>Trends in Molecular Medicine</i> , 2008, 14, 228-235.	3.5	64
9	M2 Macrophage/Microglial Cells Induce Activation of Stat3 in Primary Central Nervous System Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2011, 51, 93-99.	0.3	64
10	Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki Forest virus $\alpha$ mediated complementary DNA. <i>Journal of Neurosurgery</i> , 2001, 94, 474-481.	0.9	63
11	Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. <i>Cancer Gene Therapy</i> , 2001, 8, 796-802.	2.2	60
12	Radiation-induced gliomas: a comprehensive review and meta-analysis. <i>Neurosurgical Review</i> , 2018, 41, 719-731.	1.2	60
13	Gene expression signature $\alpha$ -based prognostic risk score in patients with glioblastoma. <i>Cancer Science</i> , 2013, 104, 1205-1210.	1.7	56
14	Tumor mRNA $\alpha$ -loaded dendritic cells elicit tumor-specific CD8 $\alpha$ cytotoxic T cells in patients with malignant glioma. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 632-637.	2.0	54
15	Medical management of brain metastases from lung cancer (Review). <i>Oncology Reports</i> , 2009, 22, 1269-76.	1.2	54
16	Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. <i>Journal of Neurosurgery</i> , 2003, 99, 746-753.	0.9	52
17	Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus $\alpha$ mediated interleukin-12. <i>Journal of Neurosurgery</i> , 2002, 97, 611-618.	0.9	50
18	Dendritic cell-based glioma immunotherapy (review). <i>International Journal of Oncology</i> , 2003, 23, 5-15.	1.4	48

#	ARTICLE	IF	CITATIONS
19	Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. <i>Cancer Biology and Therapy</i> , 2010, 10, 1266-1279.	1.5	46
20	The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2018, 58, 95-101.	0.3	43
21	Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. <i>Cancer Science</i> , 2013, 104, 1285-1294.	1.7	39
22	Dendritic-cell- and peptide-based vaccination strategies for glioma. <i>Neurosurgical Review</i> , 2009, 32, 265-273.	1.2	38
23	Radiation-Induced Malignant Peripheral Nerve Sheath Tumors: A Systematic Review. <i>World Neurosurgery</i> , 2017, 105, 961-970.e8.	0.7	38
24	Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma. <i>Oncotarget</i> , 2018, 9, 19065-19078.	0.8	37
25	Gene Expression Signature-Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 5672-5681.	3.2	35
26	Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review. <i>Cancers</i> , 2017, 9, 103.	1.7	35
27	Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. <i>Journal of Neuro-Oncology</i> , 2005, 72, 107-113.	1.4	34
28	Induction of Antigen-Specific Immune Responses Against Malignant Brain Tumors by Intramuscular Injection of Sindbis DNA Encoding Gp100 and IL-18. <i>DNA and Cell Biology</i> , 2005, 24, 317-324.	0.9	32
29	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. <i>Oncotarget</i> , 2018, 9, 27471-27486.	0.8	30
30	Cytokine gene expression on glioma cell lines and specimens. <i>Journal of Neuro-Oncology</i> , 1994, 21, 243-247.	1.4	29
31	Growth inhibition of human glioma cells modulated by retrovirus gene transfection with antisense IL-8. <i>Journal of Neuro-Oncology</i> , 1995, 25, 59-65.	1.4	29
32	Effects of Irradiation on Cytokine Production in Glioma Cell Lines. <i>Neurologia Medico-Chirurgica</i> , 1993, 33, 744-748.	1.0	27
33	Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients. <i>Oncology Reports</i> , 2006, 16, 1093.	1.2	27
34	Characteristics of patients with brain metastases from lung cancer in a palliative care center. <i>Supportive Care in Cancer</i> , 2011, 19, 467-473.	1.0	26
35	Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. , 2017, 37, 5655-5666.		26
36	Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. <i>Neurosurgical Focus</i> , 2000, 9, 1-6.	1.0	25

#	ARTICLE	IF	CITATIONS
37	Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 21-25.	0.3	25
38	Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL. <i>Scientific Reports</i> , 2019, 9, 10004.	1.6	24
39	Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells. <i>Journal of Neuro-Oncology</i> , 1999, 43, 27-34.	1.4	23
40	Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki Forest virus-mediated tumor complementary DNA. <i>Journal of Neurosurgery</i> , 2002, 97, 1184-1190.	0.9	23
41	Results of Treatment of 112 Cases of Primary CNS Lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 373-380.	0.6	23
42	Frequency and risk factors for subsyndromal delirium in an intensive care unit. <i>Intensive and Critical Care Nursing</i> , 2018, 47, 15-22.	1.4	23
43	Promising Prognosis Marker Candidates on the Status of Epithelial-Mesenchymal Transition and Glioma Stem Cells in Glioblastoma. <i>Cells</i> , 2019, 8, 1312.	1.8	23
44	MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma. <i>PLoS ONE</i> , 2019, 14, e0210400.	1.1	23
45	Molecularly targeted therapies for glioma. <i>Annals of Neurology</i> , 2009, 66, 717-729.	2.8	22
46	Trilateral retinoblastoma: A systematic review of 211 cases. <i>Neurosurgical Review</i> , 2019, 42, 39-48.	1.2	21
47	Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. <i>Oncology Reports</i> , 2006, 15, 1569.	1.2	20
48	Radiation-Induced Sarcomas of the Central Nervous System: A Systematic Review. <i>World Neurosurgery</i> , 2017, 98, 818-828.e7.	0.7	19
49	Increased expression of CCAAT/enhancer binding protein $\beta$ correlates with prognosis in glioma patients. <i>Oncology Reports</i> , 2006, 15, 595.	1.2	18
50	CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma multiforme. <i>PLoS ONE</i> , 2019, 14, e0216825.	1.1	17
51	miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma. <i>PLoS ONE</i> , 2020, 15, e0229577.	1.1	16
52	Development of Improved Sindbis Virus-Based DNA Expression Vector. <i>DNA and Cell Biology</i> , 2004, 23, 75-80.	0.9	15
53	Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma. <i>Annals of Hematology</i> , 2005, 84, 447-455.	0.8	15
54	Peptide-based immunotherapeutic approaches to glioma: a review. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 645-649.	1.4	15

#	ARTICLE	IF	CITATIONS
55	Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2 <sup>+</sup> glioma patients. <i>Cancer Science</i> , 2008, 99, 1656-1662.	1.7	14
56	Metabolome analysis reveals excessive glycolysis via PI3K/AKT/mTOR and RAS/MAPK signaling in methotrexate-resistant primary CNS lymphoma-derived cells. <i>Clinical Cancer Research</i> , 2020, 26, clincanres.3851.2018.	3.2	14
57	Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24 <sup>+</sup> glioma patients. <i>Oncology Reports</i> , 2007, 17, 629-36.	1.2	14
58	Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen. <i>Leukemia and Lymphoma</i> , 2007, 48, 1119-1126.	0.6	13
59	Dendritic Cell Vaccines. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 187-200.	0.8	13
60	Radiation-Induced Schwannomas and Neurofibromas: A Systematic Review. <i>World Neurosurgery</i> , 2017, 104, 713-722.	0.7	13
61	Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24 <sup>+</sup> malignant glioma patients. <i>Oncology Reports</i> , 2008, 19, 1277-83.	1.2	13
62	Dendritic cell-based glioma immunotherapy (Review). <i>International Journal of Oncology</i> , 2003, 23, 5.	1.4	12
63	Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature. <i>Journal of Neuro-Oncology</i> , 2014, 117, 261-268.	1.4	12
64	Isolation and characterization of an N-linked oligosaccharide that is increased in glioblastoma tissue and cell lines. <i>International Journal of Oncology</i> , 2005, 27, 1231.	1.4	11
65	Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system. <i>Journal of Neurosurgery</i> , 2008, 109, 536-546.	0.9	11
66	Immunological analysis of the rats with anterior hypothalamic lesions. <i>Journal of Neuroimmunology</i> , 1993, 48, 45-52.	1.1	10
67	CCAAT/enhancer binding proteins are expressed in the gerbil hippocampus after transient forebrain ischemia. <i>Neuroscience Letters</i> , 2003, 337, 106-110.	1.0	10
68	Assessment of autonomic nervous system function in nursing students using an autonomic reflex orthostatic test by heart rate spectral analysis. <i>Biomedical Reports</i> , 2015, 3, 831-834.	0.9	10
69	Novel immunotherapeutic approaches to glioma. <i>Current Opinion in Molecular Therapeutics</i> , 2006, 8, 46-51.	2.8	10
70	Comparison of Stereotactic Aspiration, Craniotomy, and Conservative Treatment for Putaminal Hemorrhage. <i>Neurologia Medico-Chirurgica</i> , 1988, 28, 986-990.	1.0	9
71	Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma—A preliminary report. <i>Leukemia and Lymphoma</i> , 2007, 48, 1019-1022.	0.6	9
72	Secondary glioma following acute lymphocytic leukemia: therapeutic implications. <i>Neurosurgical Review</i> , 2017, 40, 549-557.	1.2	9

#	ARTICLE	IF	CITATIONS
73	GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. <i>Scientific Reports</i> , 2020, 10, 8435.	1.6	9
74	Late relapse of primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 475-477.	0.6	8
75	Immunohistochemical Analysis of Tumor-infiltrating Lymphocytes and Adhesion Molecules (ICAM-1.) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	1.0	7
76	Immunohistochemical analysis of myelination following hemicranial irradiation in neonatal rats. <i>Neuroscience Letters</i> , 2003, 353, 131-134.	1.0	7
77	Alphavirus vectors for cancer gene therapy (Review). <i>International Journal of Oncology</i> , 2004, 24, 919.	1.4	7
78	Management of refractory or relapsed primary central nervous system lymphoma (Review). <i>Molecular Medicine Reports</i> , 2009, 02, 879-85.	1.1	7
79	Secondary Craniofacial Sarcomas Following Retinoblastoma: A Systematic Review. <i>World Neurosurgery</i> , 2017, 101, 722-730.e4.	0.7	7
80	Effects and safety of mechanical bathing as a complementary therapy for terminal stage cancer patients from the physiological and psychological perspective: a pilot study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 1066-1072.	0.6	7
81	Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells. <i>BMC Cancer</i> , 2019, 19, 910.	1.1	7
82	Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1020-1029.	1.0	7
83	Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma. <i>PLoS ONE</i> , 2021, 16, e0251272.	1.1	7
84	Isolation and characterization of an N-linked oligosaccharide that is increased in glioblastoma tissue and cell lines. <i>International Journal of Oncology</i> , 2005, 27, 1231-9.	1.4	7
85	Effects of ACNU and Cranial Irradiation on the Mouse Immune System. <i>Neurologia Medico-Chirurgica</i> , 1993, 33, 65-70.	1.0	6
86	Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: A preliminary study. <i>Leukemia and Lymphoma</i> , 2007, 48, 1429-1433.	0.6	6
87	Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients. <i>International Journal of Oncology</i> , 2012, 40, 721-30.	1.4	6
88	Gene therapy of brain tumor with endostatin. <i>Drugs of Today</i> , 2004, 40, 931.	2.4	6
89	Radiation-Induced Glioblastoma Following Radiotherapy for Pituitary Adenomas: Marked Response to Chemotherapy. <i>Journal of Neurology &amp; Neurophysiology</i> , 2013, 04, .	0.1	6
90	Advances for the treatment of primary central nervous system lymphoma (review). <i>Oncology Reports</i> , 2004, 12, 563-8.	1.2	6

#	ARTICLE	IF	CITATIONS
91	Effects of Irradiation on the Expression of the Adhesion Molecules (NCAM, ICAM-1) by Glioma Cell Lines. <i>Neurologia Medico-Chirurgica</i> , 1993, 33, 749-752.	1.0	5
92	Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. <i>Oncology Reports</i> , 2007, , .	1.2	5
93	Thr160 of Axin1 is critical for the formation and function of the $\beta^2$ -catenin destruction complex. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 411-415.	1.0	5
94	Long-term survivors of primary central nervous system lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 101-107.	0.6	5
95	Medical Management of Brain Metastases from Lung Cancer. , 0, , .		4
96	Changes in Cerebral Hemodynamics after Extracranial-intracranial Bypass. <i>Neurologia Medico-Chirurgica</i> , 1988, 28, 981-985.	1.0	3
97	Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. <i>Oncology Reports</i> , 2008, , .	1.2	2
98	Radiation-Induced Glioma. , 2015, , .		2
99	Concerns and Returns to Work in Patients with Breast Cancer Receiving Outpatient Chemotherapy: a Pilot Study. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2019, 6, 187-192.	0.7	2
100	Whole-Genome Sequencing of Primary Central Nervous System Lymphoma and Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4112-4112.	0.6	2
101	Ostip2, a Novel Oncoprotein that Associates with the Rho Exchange Factor Ost. <i>DNA and Cell Biology</i> , 2001, 20, 383-390.	0.9	1
102	Primary Central Nervous System Lymphoma â Recent Advance on Clinical Research. , 2013, , .		1
103	Experiences and Expectations for Glioma Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2014, 4, 355.	1.3	1
104	Prognostic significance of S-phase fractions in peritumoral invading zone analyzed by laser scanning cytometry in patients with high-grade glioma: A preliminary study. <i>Oncology Letters</i> , 2016, 11, 2106-2110.	0.8	1
105	Advances for the treatment of primary central nervous system lymphoma (review). <i>Oncology Reports</i> , 0, , .	1.2	1
106	Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles. <i>International Journal of Oncology</i> , 2003, 23, 913-23.	1.4	1
107	Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles. <i>International Journal of Oncology</i> , 2003, 23, 913.	1.4	0
108	277. Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial. <i>Molecular Therapy</i> , 2006, 13, S106.	3.7	0

#	ARTICLE	IF	CITATIONS
109	Gene Expression Signature-Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma. <i>Annals of Oncology</i> , 2014, 25, v58.	0.6	0
110	Immunotherapeutic Approach for Glioma by Alphaviruses as Positive Strand RNA Viruses. , 2009, , 125-140.		0
111	Antisense DNA Approach to the Growth of Human Glioma Cells. , 1996, , 441-447.		0